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tephen G. Ellis, MD
leveland, Ohio
“Third PCI patient ever treated. Forty-three year old man
with severe angina pectoris since September, 1977.
First angiogram (November 11) revealed severe stenosis
of the main L.C.A. . .” (see Fig. 1). (The patient expired
suddenly about 4 months after this procedure.)
—Gruntzig (1)
“From a large prospective randomized study, data relating to
a subgroup of 113 patients with angina pectoris and a
significant lesion of the left main coronary artery were analyzed.
The proportion surviving 24 months was clearly larger
in the surgically treated group (p  0.02).”
—Takaro (2)
onsequent principally to the demonstration of survival
enefit with bypass surgery compared with optimal medical
herapy in the VA Cooperative Trial in 1976 (2), but also
ue to poor initial results and the unpredictability of early
alloon angioplasty in this setting (1,3), bypass surgery
ecame the standard treatment for unprotected left main
oronary disease (ULMT) and percutaneous coronary inter-
ention (PCI) was strongly discouraged.
See pages 584, 595, 602, 612, 624, and 632
Balloon angioplasty was occasionally performed, however,
specially for patients with very high expected surgical risk. As
CI results became more predictable in the late 1980s, first
ith directional coronary atherectomy and later with stenting,
ntrepid investigators, particularly from Asian societies shun-
ing surgically invasive procedures, (e.g., S. J. Park, Hideo
amai, Masakiyo Nobuyoski) and elsewhere (e.g., Carlos
acaya, Antonio Colombo) began to experiment with a more
outine use of PCI for ULMT disease (4,5).
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.s
From the Cleveland Clinic, Cleveland, Ohio. Dr. Ellis is a consultant for Abbott
ascular and Cordis Corporation.We had the opportunity to initiate a collaborative effort
o collect consecutive cases from experienced laboratories
rom 1993 to 1998. This, the largest study of its kind at the
ime, demonstrated in 279 patients considerable heteroge-
eity of results, but excellent outcomes in the subgroup of
atients 65 years old with left ventricular ejection fraction
30% and no cardiogenic shock (no periprocedural and
.4% 1-year mortality). One-year post-discharge mortality
as worrisomely high (10%) and related more to left
entricular function than extent of coronary artery disease,
aising questions about the impact of restenosis of this
ritical site in patients with impaired left ventricular func-
ion (6,7).
Several key advances have occurred since the 1990s,
eading to yet safer results: better antiplatelet therapy, the
se of intravascular ultrasound, and drug-eluting stents
DES), in particular. Optimal medical therapy including
tatin use is also important.
As the results from more current registries proved en-
ouraging, the impetuous was provided for randomized
rials to gain more definitive answers about optimal treat-
ent. Now that we have 2-year follow-up results from the
andomized SYNTAX (Synergy Between Percutaneous
oronary Intervention With Taxus and Cardiac Surgery)
rial (8), it is worth reflecting upon where the present
nowledge base stands.
Before doing so however, we should review the role and
imitations of both registries and randomized clinical trials
RCTs). Registry results reflect outcomes after the physi-
ians have chosen what they believe to be the best treatment
or each patient. Patients treated with PCI or bypass surgery
re inherently different. Registry results are typically incom-
letely monitored for quality. One need only to recall the
onclusions of previous registries—that DES kill patients
ompared to bare-metal stents (BMS) (SCAAR [Swedish
oronary Angiography and Angioplasty Registry]) (9), that
irth control pills are cardioprotective against atherothrom-
osis in post-menopausal women, not to mention that mega
eta-analyses of registries suggest DES are associated with
20% reduction in mortality compared with BMS (a
nding that has absolutely no replication when meta-
nalysis is confined to RCT)—to understand the limitations
f registry data. Even propensity analysis, in its various
terations, has major limitations: 1) If the model predicting
reatment allocation is quite good, then there are very few
atients with overlapping risks to be studied. 2) If the
redictive model is poor, then there really is no risk
djustment. Poor understanding of these concepts is espe-
ially relevant in this era of “comparative effectiveness
esearch,” with the risk that careless interpretation of study
ata will lead to bad policy emanating from Washington,
.C. On the other hand, RCT results often suffer from
uspect external validity. For example, patients recruited for
uch trials are often not typical of those in clinical practice,
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643ften being younger and with fewer clinical comorbidities.
mportantly, as differential direction of treatment effect
Figure 1. Balloon Angioplasty Patient’s Coronary Lesion and
its Treatment
Still frame images of Dr. Gruntzig’s third balloon angioplasty patient’s coronary
lesion and its treatment. Reprinted with permission from Gruntzig et al. (1).mong subgroups is rare, a logical analytic sequence is to ierform registry analyses of patients excluded from RCTs
fter the treatment benefit of the given intervention has
een demonstrated in RCTs, so as to give insight as to
hether or not the RCT results are generalizable (acknowl-
dging the limitations of registry data). Randomized trials
lso have to have sufficient sample size to have power be
certain” of results and use end points chosen for their
linical meaningfulness and not for sample size convenience.
astly, but most importantly perhaps, is the recognition that
atients are different and that “one size doesn’t always fit
ll.”
In this issue of JACC: Cardiovascular Interventions, 6
rticles attempt to extend knowledge in this particular
linical realm.
Three of these reports focus on defining factors predictive
f outcomes with percutaneous and/or surgical intervention.
im et al. (10) report results of application of the SYNTAX
core in 819 PCI and 761 bypass patients from a large
ulticenter Asian registry. Patients were followed for 3
ears. The SYNTAX score was modestly predictive of
-year outcomes in patients treated with DES, less predic-
ive with outcomes after placement of BMS, and very poorly
redictive of long-term outcomes after bypass surgery. The
YNTAX score tertile was not helpful in discrimination of
isk between PCI and bypass surgery (in contradistinction to
he prediction of 1-year outcomes in the SYNTAX trial
tself). Other studies have shown variable outcomes. Kim et
l. (10) suggest that parameters describing clinical risk
rofile might be useful in conjunction with scores such as
he SYNTAX score, which focus on patient anatomy. In
articular, their results draw focus to the impact of chronic
enal insufficiency, prior congestive heart failure or cerebro-
ascular disease, diabetes, and chronic lung disease. Chen et
l. (11) compare the predictive value of the SYNTAX score
nd a broad-based, 51-element NERS (Novel Risk Strati-
cation) score derived from analysis of a prior ULMT PCI
egistry, on major adverse cardiac events. The latter score
ignificantly outperformed the SYNTAX score for several
utcomes, but as the original model was clearly overfitted
126 variables tested, 260 patients), it is likely this score
ould be appreciably refined and improved. Tamburino et al.
12) report the for the first time a novel approach, correlat-
ng the location of left main trunk bifurcation plaque
istribution and outcomes in 329 consecutive patients un-
ergoing left main stenting from 2 Italian centers. Patients
ith plaque occupying “the whole bifurcation” were found
o be at higher risk of subsequent need for target lesion
evascularization regardless of stenting technique.
Three other reports take a more general look at long-term
utcomes after treatment of ULMT patients. Onuma et al.
13) report the Thoraxcenter experience from 2000 to 2005
ith DES in 148 patients, compared with a historical
ontrol cohort of 79 patients treated with BMS. The
nvestigators find both the EuroSCORE (European System
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644or Cardiac Operative Risk Evaluation) and SYNTAX score
o be correlated with 4-year outcomes. The overall case mix
as complex with nearly a quarter of patients presenting
ith ST-segment elevation myocardial infarction, 8.8%
ith shock. Anatomy was also complex, with a SYNTAX
core of almost 40. As such, perhaps the 1-year all-cause
ortality of 19.6% was not particularly surprising. The
nvestigators draw attention, however, to adverse outcomes
pparent in follow-up years 3 and 4—the 10% risk of death,
n particular.
Pandya et al. (14) report a meta-analysis of studies
omparing DES and BMS in this setting, following patients
or up to 3 years after PCI. Both crude and adjusted data are
rovided. The investigators caution about the concern of
onfounding and selection bias, and suggest that direct
Figure 2. Odds Ratio of MACE Following Treatment for ULMCA in Regis-
tries and RCT
Odds ratio of major adverse cardiovascular events (MACE; death, myocar-
dial infarction, cardiovascular accident) following treatment for unprotected
left main coronary artery disease (ULMCA) in percutaneous coronary inter-
vention (PCI) versus coronary artery bypass graft (CABG) patients. Modiﬁed
from Naik et al. (28). ∆  predominantly bare-metal stents; ∆∆  predomi-
nantly drug-eluting stents; ∆∆∆  all drug-eluting stents.omparison of the overall BMS and DES rates not beerformed. That said, the investigators report similar 6- to
2-month mortalities and a very considerable reduction in
he need for target vessel/lesion revascularization with DES.
y 3 years, results favored DES for mortality and myocar-
ial infarction and target vessel/lesion revascularization.
astly, Chieffo et al. (15) report on 5-year outcomes from a
ingle Italian center, comparing findings after PCI and
ypass surgery. Two-hundred forty-nine patients were in-
luded at 5 years, and PCI appeared to be associated with a
ower rate of the composite adverse outcome of death,
yocardial infarction, or stroke, whereas bypass surgery was
orrelated with lower target vessel revascularization. There
as no significant difference relating treatment to the
ccurrence of cardiac death. Interestingly, there was nearly
% incidence of stent thrombosis.
Figure 3. Odds Ratio of Mortality Following Treatment for ULMCA in Reg-
istries and RCT
Odds ratio of mortality following treatment for unprotected left main coro-
nary artery disease in percutaneous coronary intervention versus coronary
artery bypass graft patients. Modiﬁed from Naik et al. (28). ∆  predomi-
nantly bare-metal stents; ∆∆  predominantly drug-eluting stents; ∆∆∆ 
all drug-eluting stents. MACCE  major adverse cardiac and cerebrovascu-
lar events; other abbreviations as in Figure 2.
Table 1. Selected Studies of Stenting Versus Bypass Surgery for ULMCA
First Author (Ref. #)
Single or
Multicenter Patients
DES
(%)
Risk
Adjustment
Follow-Up
Duration
(CV) Death MI Stroke
Death, MI, or
Stroke TVR/TLR
Stent CABG Stent CABG Stent CABG Stent CABG Stent CABG Limitations
Brener et al. (19) S 287 57 Propensity 3 yrs 20.0 15.0 Nonrandomized, underpowered, end point details NA
Chieffo et al. (20) S 249 100 Propensity 1 yr 2.8 6.4 0.9 1.4 0.9 0.7 19.6 3.60 Nonrandomized, underpowered
Chieffo et al. (15) S 249 100 Propensity 5 yrs 7.5 11.7 0.9 7.7 0.9 4.2 18.7 8.4 Nonrandomized, underpowered
Makikallio et al. (21) M 287 100 None 2 yrs 4.0 11.0 2.0 2.0 0 5.0 4.0 2.0 No adjustment for between-group differences, very
limited number of DES patients, underpowered,
short duration of follow-up
Palmerini et al. (22) M 311 60 Propensity 2 yrs 7.4 9.7 5.3 4.5 22.0 2.6 Nonrandomized, underpowered, adjusted, and end
point details NA
Sanmartin et al. (23) S 341 100 Propensity 3 yrs 9.0 11.0 9.0 17.0 16.0 3.0 Nonrandomized, underpowered
Serruys et al. (24) M 705 100 RCT 2 yrs 4.2* 4.4* 4.3* 4.1* 0.3* 2.7* 10.2 11.8 17.3 10.4 Subgroup of a technically negative trial, somewhat
underpowered, limited duration of follow-up
Seung et al. (18) M 792 100 Propensity 3 yrs 9.0a 6.9a 12.5a 8.0a 9.3a 1.6a Nonrandomized
White et al. (25) S 343 100 Propensity 30 months 18.9 12.7 Nonrandomized, underpowered, end point details NA
Kim et al. (10) M 1,580 79 SYNTAX score 3 yrs 6.2 9.2 7.1 10.4 10.3 2.7 Nonrandomized
*Drug-eluting stents50% of percutaneous coronary intervention; DES-specific data only (when provided): a adjusted (otherwise unadjusted) 1-year outcomes.
CABG  coronary artery bypass graft; CV  cardiovascular; DES  drug-eluting stent; M  multicenter; MI  myocardial infarction; NA  not available; RCT  randomized clinical trial; S  single center; TLR  target lesion revascularization; TVR  target vessel
revascularization; ULMCA unprotected left main coronary artery disease.
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646Treatment of this relatively small group of anatomically
nique patients, whose importance has perhaps been mag-
ified because they represent the “last bastion” of patients
equiring open heart surgery, draws an emotionally charged
ocus from competing surgeons and interventionalists. (The
rue “last bastion” is more likely patients with diffuse but
ypassable disease.) Therefore, a knowledge base for treat-
ent needs to be synthesized (Figs. 2 and 3, Table 1)
16–25), but the following information is necessary to
omplete it. 1) There is still work to be done about
iscerning among this group who would best be treated with
ach of the revascularization strategies. Data from Kim et al.
10), Chen et al. (11), and Park et al. (5) suggest caution in
sing the SYNTAX score alone to make this determination.
erhaps this is intuitive, but better scoring methodology
eeds to be flushed out from large groups of patients and
arefully studied. 2) The cardiology community needs
onger-term follow-up from large studies in which patients
ere randomized to either of these 2 revascularization
trategies. The 12- to 24-month data from the SYNTAX
rial, wherein the event curves of the DES and surgically
reated patients are largely parallel, are reassuring, but the
ppropriate time horizon for patients such as this, particu-
arly when an invasive surgical procedure is being contem-
lated, should be at least 5 years. Long-term data from the
horaxcenter is perhaps somewhat disturbing in this regard.
owever, readers should be mindful of the high-risk mix of
atients studied and also their very small number. Con-
ersely, most large reports of DES-treated patients of
ifferent levels of complexity show relatively flat event
urves 2 to 5 years after PCI (18,26,27).
At this point, because ULMT patients need treatment
oday, perhaps we can agree that most patients with very few
imple lesions in addition to their left main narrowing
typically falling into the lowest SYNTAX score tertile)
e.g., see Fig. 3A of Kim et al. [10]), and who can tolerate
ual antiplatelet therapy, be considered quite reasonable
andidates for referral for PCI. Conversely, patients with
dvanced and multiple lesions (characteristically falling into
he highest risk tertile of the SYNTAX score) are probably
est referred for open heart surgery. There remains a
elatively large number of patients with intermediate ana-
omic complexity, as well as many other subsets of patients
or which we have incomplete data (e.g., chronic renal
nsufficiency) for whom there remains considerable uncer-
ainty. Although we will have to be patient, hopefully we
ill receive more information on these patients from the
pcoming EXCEL (Evaluation of Xience Prime versus
oronary Artery Bypass Surgery for Effectiveness of Left
ain Revascularization) trial.
cknowledgment
he author would like to thank Bernie Meier, MD, for hisnsight regarding Dr. Gruntzig’s early PCI experience.eprint requests and correspondence: Dr. Stephen G. Ellis,
leveland Clinic, 9500 Euclid Avenue, J2-3, Cleveland, Ohio
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